IRWD Ironwood Pharmaceuticals Inc - Class A

Price (delayed)

$4.08

Market cap

$674.18M

P/E Ratio

5.1

Dividend/share

N/A

EPS

$0.8

Enterprise value

$991.92M

?
Relative Growth: Rel. Growth: 75
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: 98
Relative Profitability: Rel. Profitability: 94

Ironwood Pharmaceuticals is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog ...

Highlights
IRWD's P/E is 49% below its last 4 quarters average of 10.0
The company's equity rose by 47% YoY and by 25% QoQ

Key stats

What are the main financial stats of IRWD

IRWD stock price

How has the Ironwood Pharmaceuticals Inc - Class A stock price performed over time
Intraday
-5.56%
1 week
-4.23%
1 month
-3.09%
1 year
274.31%
YTD
21.07%
QTD
-3.09%

Financial performance

How have Ironwood Pharmaceuticals Inc - Class A's revenue and profit performed over time
Revenue
$389.32M
Gross profit
$389.32M
Operating income
$234.17M
Net income
$129.87M
Gross margin
100%
Net margin
33.4%
IRWD's operating margin has surged by 153% year-on-year and by 8% since the previous quarter
The net income has grown by 27% from the previous quarter
IRWD's revenue is up by 26% YoY and by 8% QoQ
Ironwood Pharmaceuticals Inc - Class A's gross profit has increased by 26% YoY and by 8% QoQ

Price vs fundamentals

How does IRWD's price correlate with its fundamentals

Growth

What is Ironwood Pharmaceuticals Inc - Class A's growth rate over time

Valuation

What is Ironwood Pharmaceuticals Inc - Class A stock price valuation
P/E
5.1
P/B
N/A
P/S
1.72
EV/EBIT
4.13
EV/EBITDA
4.07
EV/Sales
2.55
IRWD's P/E is 49% below its last 4 quarters average of 10.0
The EPS has increased by 25% since the previous quarter
The company's equity rose by 47% YoY and by 25% QoQ
IRWD's P/S is 41% below its 5-year quarterly average of 2.9 but 15% above its last 4 quarters average of 1.5
IRWD's revenue is up by 26% YoY and by 8% QoQ

Efficiency

How efficient is Ironwood Pharmaceuticals Inc - Class A business performance
The return on sales has surged by 145% year-on-year and by 9% since the previous quarter
Ironwood Pharmaceuticals Inc - Class A's return on assets has increased by 32% QoQ
Ironwood Pharmaceuticals Inc - Class A's ROIC has increased by 19% from the previous quarter

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals Inc - Class A financials performed over time
The total assets is 36% less than the total liabilities
The total assets has contracted by 34% from the previous quarter and by 17% YoY
IRWD's total liabilities is down by 31% since the previous quarter and by 31% year-on-year
The company's equity rose by 47% YoY and by 25% QoQ
IRWD's debt is down by 34% year-on-year and by 34% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.